Aldeyra Therapeutics
ALDX
96 hedge funds and large institutions have $232M invested in Aldeyra Therapeutics in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 24 increasing their positions, 36 reducing their positions, and 10 closing their positions.
80% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 10
17% more capital invested
Capital invested by funds: $197M → $232M (+$34.3M)
8% more funds holding
Funds holding: 89 → 96 (+7)
5.01% less ownership
Funds ownership: 63.39% → 58.37% (-5%)
33% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 36
42% less call options, than puts
Call options by funds: $1.52M | Put options by funds: $2.61M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$1.85M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$1.79M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.2M |
| 4 |
Millennium Management
New York
|
+$1.16M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$700K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.45M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$4.82M |
| 3 |
6CM
683 Capital Management
New York
|
-$3.83M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$2.45M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$2.01M |
ALDX Hedge Fund Activity: Q4 2022 in Review
96 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2022, worth a combined $232M — up 17% from $197M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new ALDX positions and 10 closed out — a net gain of 8 holders — while 24 added to existing stakes and 36 trimmed.
The largest buyer was J. Goldman & Co, adding an estimated $1.85M. The largest seller was Citadel Advisors, cutting an estimated $5.45M.
- 96 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2022, up from 89 in Q3 2022.
- Funds reported $232M of Aldeyra Therapeutics stock for Q4 2022, up 17% quarter-over-quarter.
- 18 funds opened new Aldeyra Therapeutics positions in Q4 2022 and 10 closed out, a net change of +8 holders.
- The largest Aldeyra Therapeutics buyer in Q4 2022 was J. Goldman & Co, an estimated $1.85M added.
- The largest Aldeyra Therapeutics seller in Q4 2022 was Citadel Advisors, an estimated $5.45M sold.
Based on aggregated 13F filings for Q4 2022.